JP2024518844A5 - - Google Patents

Info

Publication number
JP2024518844A5
JP2024518844A5 JP2023571586A JP2023571586A JP2024518844A5 JP 2024518844 A5 JP2024518844 A5 JP 2024518844A5 JP 2023571586 A JP2023571586 A JP 2023571586A JP 2023571586 A JP2023571586 A JP 2023571586A JP 2024518844 A5 JP2024518844 A5 JP 2024518844A5
Authority
JP
Japan
Application number
JP2023571586A
Other languages
Japanese (ja)
Other versions
JP2024518844A (ja
JPWO2022246154A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030189 external-priority patent/WO2022246154A2/en
Publication of JP2024518844A publication Critical patent/JP2024518844A/ja
Publication of JP2024518844A5 publication Critical patent/JP2024518844A5/ja
Publication of JPWO2022246154A5 publication Critical patent/JPWO2022246154A5/ja
Pending legal-status Critical Current

Links

JP2023571586A 2021-05-20 2022-05-20 C1sに結合する抗体およびその使用 Pending JP2024518844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201952P 2021-05-20 2021-05-20
US63/201,952 2021-05-20
PCT/US2022/030189 WO2022246154A2 (en) 2021-05-20 2022-05-20 Antibodies that bind to c1s and uses thereof

Publications (3)

Publication Number Publication Date
JP2024518844A JP2024518844A (ja) 2024-05-07
JP2024518844A5 true JP2024518844A5 (https=) 2025-05-28
JPWO2022246154A5 JPWO2022246154A5 (https=) 2025-05-28

Family

ID=84141843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571586A Pending JP2024518844A (ja) 2021-05-20 2022-05-20 C1sに結合する抗体およびその使用

Country Status (5)

Country Link
US (2) US12252550B2 (https=)
EP (1) EP4340879A4 (https=)
JP (1) JP2024518844A (https=)
CN (1) CN117769434A (https=)
WO (1) WO2022246154A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023385709A1 (en) 2022-11-21 2025-06-12 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
AU2024237478A1 (en) 2023-03-16 2025-10-30 Genzyme Corporation Treatment of dry age-related macular degeneration
US20250206814A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
WO2025129535A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療c1s介導的疾病和病症的組成物、劑量和方法
US20250376511A1 (en) 2024-06-05 2025-12-11 Genzyme Corporation BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PT3415619T (pt) * 2011-04-28 2021-03-22 Univ Leland Stanford Junior Identificação de polinucleótidos associados a uma amostra
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2996722A4 (en) 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
KR20160068855A (ko) * 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
WO2016164358A1 (en) * 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
CA3055781A1 (en) 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
EP3710589A4 (en) * 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use

Similar Documents

Publication Publication Date Title
CL2025004118A1 (es) Composiciones y métodos de inhibición de la adenilato ciclasa 9 (ac9).
CL2026000107A1 (es) Estimuladores de defensa de plantas
CL2025004133A1 (es) Apósito mejorado para heridas y método para prepararlo
CL2025003850A1 (es) Variación de fuerza de trituración reducida en trituradores.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BY13175U (https=)
BY13168U (https=)
CN307046000S (https=)
CN307045152S (https=)
CN307044582S (https=)
CN307044303S (https=)
CN307046274S (https=)
BY13140U (https=)
CN307046734S (https=)
CN307047155S (https=)
CN307047933S (https=)
BY24000C1 (https=)
BY23963C1 (https=)
BY13176U (https=)
CN307045519S (https=)